Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | GAA | P10253 | 1/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.67 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.67 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.67 |
| ▸ | PPARG | P37231 | 1/20 | 0.64 |
| ▸ | PPARD | Q03181 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499504 | 1.00 | MEN1 (0.67) | MEN1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL9339706 | 0.87 | MAPT (0.68) | MEN1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL9339697 | 0.87 | MAPT (0.68) | MEN1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL28600841 | 0.86 | MAPT (0.68) | MEN1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL28608357 | 0.85 | PPARG (0.70) | MEN1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL21897755 | 0.85 | — | — | |
| SCHEMBL13359041 | 0.84 | MAPT (0.66) | MEN1MAPTRAB9AKMT2A | |
| SCHEMBL4462257 | 0.84 | MAPT (0.65) | MEN1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL4462260 | 0.84 | MAPT (0.65) | MEN1ALDH1A1LMNAGAAMAPT | |
| SCHEMBL3969013 | 0.83 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113121394-B | Preparation method of phenoxyacetic acid derivative | 中国药科大学 | 2022-11-08 | — | — | CN | claimed |
| CN-113121394-A | Preparation method of phenoxyacetic acid derivative | 中国药科大学 | 2021-07-16 | — | — | CN | claimed |
| CN-113121394-B | Preparation method of phenoxyacetic acid derivative | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-113121394-B | Preparation method of phenoxyacetic acid derivative | 中国药科大学 | 2022-11-08 | — | — | CN | disclosed |
| CN-109316601-B | Pharmaceutical composition and use thereof | 武汉朗来科技发展有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113121394-A | Preparation method of phenoxyacetic acid derivative | 中国药科大学 | 2021-07-16 | — | — | CN | disclosed |
| CN-113121394-A | Preparation method of phenoxyacetic acid derivative | 中国药科大学 | 2021-07-16 | — | — | CN | disclosed |
| EP-2571843-B1 | IMPROVED PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2017-12-27 | — | — | EP | disclosed |
| US-8765992-B2 | Preparation of chalcone derivatives | GENFIT (FR) | 2014-07-01 | — | — | US | disclosed |
| US-8461212-B2 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2013-06-11 | — | — | US | disclosed |
| US-20130131372-A1 | PREPARATION OF CHALCONE DERIVATIVES | GENFIT (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | GENFIT (FR) | 2006-06-29 | — | — | US | disclosed |
| EP-1644312-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | Genfit (FR) | 2006-04-12 | — | — | EP | disclosed |
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | GENFIT (FR) | 2005-08-11 | — | — | US | disclosed |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | GENFIT (FR) | 2005-08-04 | — | — | US | disclosed |
| EP-1525177-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-27 | — | — | EP | disclosed |
| EP-1519908-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES THEREOF | Genfit (FR) | 2005-04-06 | — | — | EP | disclosed |
| WO-2005005369-A1 | PREPARATION OF 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2005-01-20 | — | — | WO | disclosed |
| WO-2004005243-A2 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005233-A1 | SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES AND PREPARATION AND USES THEREOF | GENFIT (FR) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176808-A1 | Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof | PGF, PTGS1, PTGES3 | MEN1 3869/4885ALDH1A1 231/4885LMNA 1823/4885 |
| US-20050171149-A1 | Composition based on substituted 1,3-diphenylprop-2-en-1-one derivatives, preparation and uses thereof | BRCA1, LOXL1, APOL1 | MEN1 1522/4885ALDH1A1 518/4885LMNA 100/4885 |
| US-20060142611-A1 | Preparation of 1,3-diphenylprop-2-en-1-one derivatives | DPEP1, PKD1, ENPP1 | MEN1 1780/4885ALDH1A1 238/4885LMNA 894/4885 |
| US-20130131372-A1 | PREPARATION OF CHALCONE DERIVATIVES | SULT1E1, HCCS, STS | MEN1 2269/4885ALDH1A1 874/4885LMNA 3079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.